Newron Pharmaceuticals Statistics
Total Valuation
Newron Pharmaceuticals has a market cap or net worth of CHF 161.81 million. The enterprise value is 195.15 million.
Market Cap | 161.81M |
Enterprise Value | 195.15M |
Important Dates
The next estimated earnings date is Monday, September 30, 2024.
Earnings Date | Sep 30, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Newron Pharmaceuticals has 19.06 million shares outstanding. The number of shares has increased by 48.58% in one year.
Shares Outstanding | 19.06M |
Shares Change (YoY) | +48.58% |
Shares Change (QoQ) | +33.52% |
Owned by Insiders (%) | 5.10% |
Owned by Institutions (%) | 4.81% |
Float | 18.09M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 12.86 |
PS Ratio | 17.97 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -12.92 |
EV / Sales | 23.15 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -20.65 |
Financial Position
The company has a current ratio of 0.68
Current Ratio | 0.68 |
Quick Ratio | 0.61 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | -4.77 |
Interest Coverage | -2.79 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -23.05% |
Return on Capital (ROIC) | -28.99% |
Revenue Per Employee | 383,178 |
Profits Per Employee | -686,394 |
Employee Count | 22 |
Asset Turnover | 0.29 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.31% in the last 52 weeks. The beta is 0.70, so Newron Pharmaceuticals's price volatility has been lower than the market average.
Beta (5Y) | 0.70 |
52-Week Price Change | +43.31% |
50-Day Moving Average | 7.99 |
200-Day Moving Average | 7.83 |
Relative Strength Index (RSI) | 61.02 |
Average Volume (20 Days) | 39,490 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Newron Pharmaceuticals had revenue of CHF 8.43 million and -15.10 million in losses. Loss per share was -0.85.
Revenue | 8.43M |
Gross Profit | 8.43M |
Operating Income | -10.82M |
Pretax Income | -15.08M |
Net Income | -15.10M |
EBITDA | -10.70M |
EBIT | -10.82M |
Loss Per Share | -0.85 |
Balance Sheet
The company has 11.73 million in cash and 45.06 million in debt, giving a net cash position of -33.34 million or -1.75 per share.
Cash & Cash Equivalents | 11.73M |
Total Debt | 45.06M |
Net Cash | -33.34M |
Net Cash Per Share | -1.75 |
Equity (Book Value) | -27.84M |
Book Value Per Share | -1.56 |
Working Capital | -8.63M |
Cash Flow
In the last 12 months, operating cash flow was -9.44 million and capital expenditures -10,238, giving a free cash flow of -9.45 million.
Operating Cash Flow | -9.44M |
Capital Expenditures | -10,238 |
Free Cash Flow | -9.45M |
FCF Per Share | -0.50 |
Margins
Gross margin is 100.00%, with operating and profit margins of -128.40% and -179.13%.
Gross Margin | 100.00% |
Operating Margin | -128.40% |
Pretax Margin | -178.87% |
Profit Margin | -179.13% |
EBITDA Margin | -126.89% |
EBIT Margin | -128.40% |
FCF Margin | -112.08% |
Dividends & Yields
Newron Pharmaceuticals does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -48.58% |
Shareholder Yield | -48.58% |
Earnings Yield | -9.97% |
FCF Yield | -5.84% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |